HIK.L vs VTRS
HIK.L: Hikma Pharmaceuticals is a global provider of generic, branded, and injectable medicines with a significant footprint in the US and MENA markets. VTRS: Viatris is a global healthcare company providing a broad range of high-quality, affordable medicines across both developed and emerging markets.
Side-by-side fundamentals
| Metric | HIK.L | VTRS | Edge |
|---|---|---|---|
| Price | £16.46 | $17.44 | |
| Market cap | $4.5B | $20.0B | |
| Net margin | +12.2% | -24.6% | HIK.L higher |
| Gross margin | +43.0% | +35.1% | HIK.L higher |
| Operating margin FY2025, SEC XBRL | n/a | -18.6% | |
| ROE | +15.6% | -23.9% | HIK.L higher |
| ROA FY2025, SEC XBRL | n/a | -9.5% | |
| Debt / equity as of 2026-09-02 | n/a | 0.94 | |
| Revenue growth (YoY) as of 2026-09-02 | n/a | +4.4% | |
| Revenue CAGR (3y) SEC XBRL | n/a | -4.2% | |
| Dividend yield as of 2026-09-02 | n/a | +2.8% | |
| Dividend streak (yrs) SEC XBRL | n/a | 5 | |
| Beta as of 2026-09-02 | n/a | 0.75 | |
| 1-year return | -9.8% | +74.9% | VTRS higher |
Fundamentals: SEC XBRL company filings and annual report filings for the figures marked with a fiscal year, and market data, as of 2026-09-02 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-07.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.